873011-21-3

Basic information

• Product Name: [1,1'-BIPHENYL]-4-ACETIC ACID,4'-HYDROXY-,METHYL ESTER
• Synonyms: [1,1'-BIPHENYL]-4-ACETIC ACID,4'-HYDROXY-,METHYL ESTER
• CAS NO: 873011-21-3
• Molecular Formula: C₁₅H₁₄O₃
• Molecular Weight: 0
• Mol File: 873011-21-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: [1,1'-BIPHENYL]-4-ACETIC ACID,4'-HYDROXY-,METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: [1,1'-BIPHENYL]-4-ACETIC ACID,4'-HYDROXY-,METHYL ESTER(873011-21-3)
• EPA Substance Registry System: [1,1'-BIPHENYL]-4-ACETIC ACID,4'-HYDROXY-,METHYL ESTER(873011-21-3)

Safety Data

• Hazardous Substances Data: 873011-21-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
[1,1'-BIPHENYL]-4-ACETIC ACID,4'-HYDROXY-,METHYL ESTER is used as a precursor or intermediate for the synthesis of various drugs and pharmaceuticals, contributing to the development of new medications.
Used in Chemical Industry:
[1,1'-BIPHENYL]-4-ACETIC ACID,4'-HYDROXY-,METHYL ESTER serves as a building block for the production of various organic compounds, playing a crucial role in the synthesis of specialty chemicals.
Used in Organic Synthesis and Medicinal Chemistry Research:
[1,1'-BIPHENYL]-4-ACETIC ACID,4'-HYDROXY-,METHYL ESTER may have potential applications in organic synthesis and medicinal chemistry research, where it can be utilized to explore new chemical reactions and develop novel therapeutic agents.

Upstream product

• 352652-78-9 methyl (4'-methoxy-1,1'-biphenyl-4-yl) acetate 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 
• 5720-07-0 4-methoxyphenylboronic acid 
• 41841-16-1 (4-bromo-phenyl)-acetic acid methyl ester 
• 67-56-1 methanol 
• 51350-23-3 2-(4'-hydroxy-[1,1'-biphenyl]-4-yl)acetic acid 

Downstream Products

• 873011-29-1 methyl (4'-{[2-(dimethoxymethyl)-3-(methoxymethoxy)-4-(trifluoromethyl)benzyl]oxy}-1,1'-biphenyl-4-yl)acetate 
• 873011-30-4 methyl (4'-{[3-(allyloxy)-2-formyl-4-(trifluoromethyl)benzyl]oxy}-1,1'-biphenyl-4-yl)acetate 
• 873011-31-5 tert-butyl 2-hydroxy-6-[({4'-[(methoxycarbonyl)methyl]-1,1'-biphenyl-4-yl}oxy)methyl]-3-(trifluoromethyl)benzoate 
• 873010-88-9 (4'-{[2-(tert-Butoxycarbonyl)-3-hydroxy-4-(trifluoromethyl)benzyl]oxy}-1,1'-biphenyl-4-yl)acetic acid 
• 873011-22-4 tert-butyl 6-fluoro-2-[((4'-[(methoxycarbonyl)methyl]-1,1'-biphenyl-4-yl)oxy)methyl]-1H-indole-1-carboxylate 

Relevant articles and documents

Discovery and structure-guided optimization of tert-butyl 6-(phenoxymethyl)-3-(trifluoromethyl)benzoates as liver X receptor agonists

Abstract To obtain potent liver X receptor (LXR) agonists, a structure-activity relationship study was performed on a series of tert-butyl benzoate analogs. As the crystal structure analysis suggested applicable interactions between the LXR ligand-binding

BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS

A superior LXR modulator is provided. A compound represented by the general formula (I): [wherein R1: -COR9 (wherein R9: alkyl, optionally substituted alkoxy or optionally substituted amino); R2: H, OH, alkoxy, optionally substituted amino, etc.; R3: H, optionally substituted alkyl, cycloalkyl, optionally substituted alkoxy, optionally substituted amino, halogeno, etc.; R4 and R5: H, optionally substituted alkyl, halogeno, etc.; R6 and R7: H, alkyl; R8: -X2R10 [wherein R10: -COR11 (wherein R11 : OH, optionally substituted alkoxy, optionally substituted amino, etc.), -SO2R12 (wherein R12: optionally substituted alkyl, optionally substituted amino, etc.), tetrazol-5-yl, etc.; X2: single bond, optionally substituted alkylene, etc.]; X1: -NH-, -O-, -S-, etc.; Y1: optionally substituted phenyl, optionally substituted 5- to 6-membered aromatic heterocyclyl; Y2: optionally substituted aryl, optionally substituted heterocyclyl, etc.] and the like is provided.

TISSUE FACTOR PRODUCTION INHIBITOR

A medicament which has an activity of inhibiting production of tissue factor and comprises an LXR ligand as an active ingredient; and a medicament for treatment and/or prophylaxis of vascular restenosis following angioplasty, endarterectomy, percutaneous transluminal coronary angioplasty (PTCA) or stent implantation, or treatment and/or prophylaxis of blood coagulation diseases, diseases induced by platelet aggregation including stable or unstable angina pectoris, cardiovascular and cerebrovascular diseases including thromboembolism formation diseases accompanying diabetes, rethrombosis following thrombolysis, cerebral ischemic attack, infarction, stroke, ischemia-derived dementia, peripheral artery disease, thromboembolism formation diseases during use of an aorta-coronary artery bypass, glomerulosclerosis, renal embolism, tumor or cancer metastasis, which comprises an LXR ligand as an active ingredient.

BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS

Disclosed is an excellent LXR modulator. Specifically disclosed is a compound represented by the general formula (I) below or the like. (I) [In the formula, R1 represents a -COR9 (wherein R9 represents an alkyl, optionally substituted alkoxy or optionally substituted amino); R2 represents an H, OH, alkoxy, optionally substituted amino or the like; R3 represents an H, optionally substituted alkyl, cycloalkyl, optionally substituted alkoxy, optionally substituted amino, halogeno or the like; R4 and R5 respectively represent an H, optionally substituted alkyl, halogeno or the like; R6 and R7 respectively represent an H or alkyl; R8 represents a -X2R10 [wherein R10 represents a -COR11 (wherein R11 represents an OH, optionally substituted alkoxy, optionally substituted amino or the like), -SO2R12 (wherein R12 represents an optionally substituted alkyl, optionally substituted amino or the like), tetrazole-5-yl or the like; and X2 represents a single bond, optionally substituted alkylene or the like]; X1 represents an -NH-, -O-, -S- or the like; Y1 represents an optionally substituted phenyl or optionally substituted 5-membered or 6-membered aromatic heterocyclyl; and Y2 represents an optionally substituted aryl, substituted heterocyclyl or the like.]

SUBSTITUTED INDOLE COMPOUND

Disclosed is an excellent LXR modulator. A compound represented by the general formula (I): (I) wherein R1, R2, R3 and R4: H, an alkyl which may be substituted, OH, an alkoxy which may be substituted, an amino which may be substituted, a halogeno, a phenyl or the like; R5: H or an alkyl; R6: -COR8 (wherein R8: an alkoxy which may be substituted, a phenyloxy which may be substituted, an amino which may be substituted, or the like), -SO2R9 (wherein R9: an alkyl which may be substituted, a phenyl which may be substituted or a heterocyclyl which may be substituted), or an alkyl which may be substituted; R7: -X2R10 [wherein R10: -COR11 (where R11: OH, an alkoxy which may be substituted or an amino which may be substituted), -SO2R12 (where R12: an alkyl which may be substituted or amino which may be substituted), -N(R13)COR14 (where R13: H or an alkyl which may be substituted; R14: H or an alkyl which may be substituted), -N(R13)SO2R15 (where R13: as defined above; R15: an alkyl which may be substituted) or tetrazol-5-yl; and X2: a single bond or an alkylene which may be substituted]; X1: a methylene which may be substituted; Y1: a phenyl which may be substituted or a heterocyclyl which may be substituted; and Y2: an aryl which may be substituted, a heterocyclyl which may be substituted or the like], or the like.